Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction

Expert Review of Anticancer Therapy

Volumn 2, Issue 6, 2002, Pages 611-614

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; APC PROTEIN; BCR ABL PROTEIN; CARBOPLATIN; CISPLATIN; GEFITINIB; GEMCITABINE; HEAT SHOCK PROTEIN 90; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAPAMYCIN DERIVATIVE; RAS PROTEIN; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; ONCOGENE; PROSTATE CANCER; SIDE EFFECT; TUMOR CELL; DRUG COMBINATION; DRUG EFFECT; GENE THERAPY; GENETICS; GENOME; NEOPLASM; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; GENE THERAPY; GENOME, HUMAN; HUMANS; NEOPLASMS; ONCOGENES; PIPERAZINES; PYRIMIDINES; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 0036906443     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.6.611     Document Type: Editorial

References (24)

1. Workman P. Scoring a bulls-eye against cancer genome targets. Curr. Opin. Pharmacol. 1, 342-352 (2001).
2. Druker B. ST1571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol. Med 8(Suppl.) S14-S18 (2002).
3. De Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8(Suppl.) S19-S26 (2002).
4. Workman P, Kaye SB (Eds). A Trends Guide to Cancer Therapeutics. Trends Mol. Med 8(Suppl. 4)(2002).
5. Hall AG, Irving J. New drugs, new drug resistance mechanisms. Exp. Rev. Anticancer Ther. 2(1), 239-340 (2002).
6. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
7. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 287, 1969-1973 (2001).
8. Wooster R. Cancer and the Human Genome Project. Lancet Oncol. 2(3), 176 (2001).
9. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2001).
10. Vogelstein B, Kinzler K. The multistep nature of cancer. Trends Genet. 9, 138-141 (1993).
11. Marx J. Debate surges over the origins of genomic defects in cancer. Science 297, 544-546 (2002).
12. Weinstein IB. Addiction to oncogenes. Science 297, 63-64 (2002).
13. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 10031-10033 (2001).
14. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin. Pharmacother. 3, 709-718 (2002).
15. Lyons JF, Wilheim S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219-225 (2001).
16. Herrera R, Sebolt-Leopold JS. Unravelling the complexities of the Raf/MAPK pathway for pharmacological intervention. Trends Mol. Med. 8, S27-S31 (2002).
17. McGill GG, Horstmann M, Winlund HR et al. Bcl2 regulation by the melanocyte master regulator MitF modulates lineage survival and melanoma cell viability. Cell 109, 707-718 (2002).
18. Maloney A, Workman P Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2, 3-24 (2002).
19. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55-S61 (2002).
20. Hostein I, Robertson D, DiStefano F et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino, 17-demethoxy geldanamycin results in cytostasis and apoptosis. Cancer Res. 61, 4003-4009 (2001).
21. Chung D. Histone modification: the'next wave' in cancer therapeutics. Trends Mol. Med. 8, S10-S11 (2002).
22. Workman P. Cancer - 21st century solutions. Biotech. Invest. Today 1, 28-32 (2002). www.investbiotech.com.
23. Giaccone G Johnson DH, Manegold C et al. A Phase III clinical trail of ZD1839 ('Iressa') in combination with gemacitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT I). Ann. Oncol. 13(Suppl. 5) 2 (2002) (Abstract 4O).
24. Johnson DH, Herbst R, Giaccone G et al. ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-niave patients with advanced non-small cell lung cancer (NSCLC): results from a Phase III trail (INTACT 2). Ann. Oncol. 13(Suppl. 5) 127 (2002) (Abstract 468O).